Breast Implants Lymphoma Cancer
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
The Law Offices of Thomas J. Lamb represents people who have been harmed by unsafe medical products, including cases involving breast implants associated with lymphoma.
In more detail, the US Food and Drug Administration (FDA) has received reports about women who have had breast implant procedures done and, later, were diagnosed with these medical conditions:
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)
- Anaplastic Large Cell Lymphoma (ALCL)
- Non-Hodgkin Lymphoma (also known as Non-Hodgkin’s Lymphoma, NHL, or just Lymphoma)
- T-cell Lymphoma
We encourage you to submit a Breast Implants Cancer Case Review – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible breast implants case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
- Summary of Information
- The Disease
- FDA Information
- Frequently Asked Questions
➤ About the Disease
➤ Risk Factors
We are here to help the women and families who have experienced this unfortunate situation. We have successfully handled personal injury and wrongful death cases for people throughout the country.
Our firm does not put its clients into large class actions lawsuits. Rather, an individual lawsuit is filed for each case. There are no costs associated with having us review your possible breast implants case.
Be assured that the information you provide to our law firm is treated as strictly confidential. Submitting a case evaluation does not obligate you to hire our law firm.
Lastly, we want you to know that you will get a reply directly from attorney Tom Lamb no later than the next business day.
Most Recent Article on This Topic
History of BIA-ALCL
In 2011, the Food and Drug Administration (FDA) reported 34 cases worldwide of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), bringing this unique disease into the public eye for the first time. Since then, BIA-ALCL has been recognized internationally as a distinct type of cancer, and prompted the 2019 US FDA Class 1 device recall as well as a worldwide voluntary recall of the Biocell textured breast implants by its manufacturer, Allergan. Many patient advocates and medical professionals have called for a more comprehensive warning of the BIA-ALCL risks associated with textured breast implants. Further, they advise patients to have a discussion with their healthcare professional before making a decision on undergoing a breast implant surgery.
To read more of this article, click below:
This January 2021 article, “Advising patients about breast implant associated anaplastic large cell lymphoma” addresses the symptoms associated with BIA-ALCL:
Patients usually experience rapid onset and spontaneous unilateral breast enlargement, found to be a fluid collection or infiltrating mass at an average of 8 to 10 years after implant placement, with the shortest interval to date being 2.2 years from initial implantation. Other reported symptoms may include a change in breast shape, breast firmness, pain, pruritic skin rashes or lesions, fever, night sweats, fatigue, capsular contracture, or lymphadenopathy. [footnotes omitted]
Currently, according the the FDA, there are only 26 cases of BIA-ALCL associated with patients who received smooth breast implants. Of those 26 cases, 7 individuals previously had a textured breast implant, while the remaining 19 individuals had an unknown previous breast implant history.
Diagnosis and Treatment of BIA-ALCL
According to the same article, “Advising patients about breast implant associated anaplastic large cell lymphoma“, patients experiencing symptoms of BIA-ALCL may warrant careful further evaluation:
For community-based practices, pathology reports that are unclear or inconclusive may be referred to a tertiary cancer center for further evaluation. As a cautionary note, diagnosed patients have been misdiagnosed with a ruptured implant, yet upon explanation the implant is found intact but with a large surrounding malignant effusion.
The management of all confirmed BIA-ALCL patients initially involves imaging for metastasis with a PET-CT scan and oncology consultation, followed by surgical excision. This involves an oncologic en bloc resection, with implant removal, total capsulectomy, and tumor excision with negative margins. If there is residual disease or there is evidence of invasion beyond the capsule, adjuvant therapies may be required such as systemic chemotherapy, targeted immune therapy, chest wall radiation, and/or stem cell transplant.
Patients similarly should know that with early detection and adequate treatment, outcomes are encouraging. Multiple studies indicate overall survival rates greater than 90% if detected in early stages. [footnotes omitted]
In summary, treatment of BIA-ALCL is easier to manage and typically has better chances of survival if caught in the early stages.
Biocell Recall and Current FDA Position
In July 2019, Allergan complied with the FDA’s request to remove its Biocell breast implant products from the US market due to high risk of BIA-ALCL with a voluntary worldwide recall of the Biocell textured breast implants. In addition, Allergan sent a letter to any US patients with Biocell textured implants for whom they had active contact information, explaining the recall and warranty program. Since then, several ongoing lawsuits have been filed against Allergan citing “negligence” and “failure to warn” as the legal basis for their compensation claims.
According to the same January 2021 article, “Advising patients about breast implant associated anaplastic large cell lymphoma“, the FDA is in the process of drafting new guidance recommendations for breast implant package labeling:
In addition to epidemiological data, patients also need to be aware of the FDA’s stance on breast implant safety. The FDA is currently in the drafting stages of new guidance recommendations for breast implants package labeling and the informed consent process. These recommendations are designed to improve patient communication so that patients are better informed about the inherent risks implicit with implants. The pending recommendations act as a supplement to the FDA’s “Saline, Silicone Gel, and Alternative Breast Implants” guidance, issued in November of 2006. The new draft specifically provides recommendations for a boxed warning, a standardized patient decision checklist, and information on BIA-ALCL, which they now list as a risk of implant-based breast surgery. Currently, the FDA does not recommend prophylactic removal of textured devices for asymptomatic patients based on the relatively low risk of developing BIA-ALCL. For patients who are having high risk textured implants explanted, their exposure to BIA-ALCL risk is not completely eradicated and this should be clearly explained to the patient as part of the informed consent if contemplating explanation surgery. The FDA has restricted any further placement of Biocell textured and unused inventory should be returned to the manufacturer. They confirm that other breast implants currently approved within the US market remain acceptably safe and efficacious. [footnotes omitted]
As always, we will continue to monitor the worldwide issues surrounding Biocell textured breast implants as well as other breast implants and BIA-ALCL. We will provide you with any new or relevant information.
We encourage you to visit our Breast Implants Lymphoma Cancer page on our website for more information. Please submit a free case evaluation if you or someone you know has been diagnosed with BIA-ALCL.
Written by: Lauren Schwab, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.
Our earlier articles about this breast implants lymphoma cancer situation:
- BIA-ALCL Case Studies Confirm Importance of Proper Treatment
- Black Box Warning Label Change for Breast Implants Finalized by the FDA
- New BIA-ALCL Cases Identified in Updated FDA Report
- Most American Women Are Unaware of BIA-ALCL
- Allergan Aesthetics Launches Tracking Campaign for U.S. Breast Implant Patients
- Advances Made in Understanding and Treatment of BIA-ALCL
- Cancer Linked to Breast Implants: Is it Considered Rare Anymore?
- FDA Proposes New Recommendations for Breast Implant Labels
- TGA Regulations on Breast Implant Products
- FDA Recalls Allergan Textured Implants
- Statistics Show An Increased Risk For BIA-ALCL With Textured Implants
- Textured Breast Implants Ban: Onto Australia
- FDA Fails When It Comes To Banning Textured Breast Implants
- Textured Breast Implants Bans on the Rise
- March 2019 FDA Meeting On Breast Implants: A Summary Of What You Need To Know
- Breast Implants FDA March 2019 Meeting: Lymphoma Cancer Was A Main Topic
- 2019 Discoveries and Warnings on Breast Implant-Associated Lymphoma
- Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
- Allergan Textured Breast Implants Recalled In Europe Due To BIA-ALCL
- FDA Provides Updated Number of Breast Implants Lymphoma Cancers
- New Data Released on Risk of Lymphoma Due to Breast Implants
- Breast Implant-Associated Lymphoma Diagnoses on the Rise
- What is the Risk of Death Due to Breast Implant-Associated Lymphoma?
- Treatments For Breast Implants Associated Lymphoma And Blood Cancer
- Breast Implants and Lymphoma: Who’s to Blame?
- Breast Implants Lymphoma Cancer: Diagnosis And Treatment Developments
- Breast Implant Lymphoma: Causes Uncertain, but Costs Undeniable
- March 2017 FDA Report: Breast Implants Linked To Lymphoma Blood Cancer
- Breast Implants Linked to Rare Lymphoma Blood Cancer